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Summary
Background Generic and disease-specific quality-of-life (QOL) questionnaires are commonly used
in subjects with allergic rhinitis (AR). AR, however, is closely associated with other disorders such as
bronchial asthma and atopic dermatitis (AD). These co-morbid associations may have an effect on
the inter-relation of generic and disease-specific QOL outcomes and the behaviour of this inter-
relation in time.
Objective To unravel the inter-relationships between the outcome of a generic instrument (SF-36)
and a disease-specific instrument (Rhinitis QOL Questionnaire (RQLQ)).
Materials and methods In the framework of a randomized clinical trial with respect to the efficacy
of impermeable bedding covers in house dust mite (HDM) allergy, SF-36 and RQLQ were
administered to 224 adults with AR and/or allergic asthma and/or AD at baseline and after 12
months of intervention. Regression analysis and canonical correlation were used to estimate overlap.
Results Overlap between SF-36 and RQLQ domains in terms of explained variance ranged from
6% to 56%. Canonical correlation yielded low coefficients (0.16–0.27). Moreover, both SF-36 and
RQLQ scores did not change significantly during the intervention.
Conclusion In patients with HDM allergy characterized by co-morbid associations, SF-36 and
RQLQ cover different aspects in QOL. It is advocated to use both simultaneously in performing
QOL studies.
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Introduction
In the last decade, interest in the impact of atopic disease on
quality of life (QOL) has grown. It is generally accepted that
disease may hamper patients in their day-to-day functioning.
As a consequence, instruments for measuring QOL have been
developed, both generic and disease specific [1–6]. In allergic
rhinitis (AR), both types of questionnaires have been used to
evaluate the burden of nasal symptoms [7–12]. Previous re-
search indicated that rhinitis-related QOL is moderately asso-
ciated with nasal symptoms and nasal hyper-reactivity [13].
In day-to-day practice, patients usually suffer from more
than one atopic disorder. The rates of AR among asthmatics
vary from 28% to 50% in studies published in the 1970s and
1980s [14, 15]. Recently, in a population-based study the
prevalence of rhinitis in patients with asthma was estimated at
78% [16]. Edfors-Lubs showed that the prevalence of rhinitis
in patients with dermatitis was 29% [14]. In a previous study,
we found that 92% of the asthmatic patients and 85% of the
patients with atopic dermatitis (AD) had nasal symptoms [17].
Despite all evidence for the high co-morbidity in atopic
disease, in daily clinical-care therapy focusses on the most
predominant disease, i.e. asthma, AD or rhinitis.
Therefore, we recently evaluated the impact of different
disorders (i.e. rhinitis, asthma and AD) and co-morbidity on
QOL in general assessed by the SF-36 in adult patients with
house dust mite (HDM) allergy [18]. This study was a part of
a large multi-centre clinical trial to investigate the effect of
impermeable bedding covers on symptoms of allergic asthma,
AR and AD. Results indicated that these patients experienced
impaired QOL. The (co)-existence of asthma, expressed in
terms of diagnostic criteria or symptom severity, or the
presence of sleep disorders as a consequence of AD impaired
QOL even further. Because of the high prevalence of rhinitis,
we could only evaluate the additional contribution of co-
existing asthma and ADs on generic QOL. However, as both
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generic and disease-specific QOL have been assessed by
questionnaires, this data set enabled us to investigate the
inter-relationship between the generic SF-36 and the disease-
specific QOL questionnaire for rhinoconjunctivitis (Rhinitis
QOL Questionnaire (RQLQ)) in a population characterized
by rhinitis and concomitant allergic disorders. Moreover, the
study design of the clinical trial permitted us to investigate the
change of this overlap during 1 year of follow-up.
Materials and methods
Study design and patients
Patients took part in a multi-centre trial to study the effect
of impermeable covers for bedding on complaints of atopic
rhinitis, atopic asthma or AD or any combination of these
conditions. Participating centres were the Allergology De-
partments of the University Hospitals of Groningen and
Rotterdam and the Dermatology Department of the Uni-
versity Hospital Utrecht. The study was approved by the
Medical Ethics Committees of all three University Hospitals
and all patients gave written informed consent. Inclusion and
exclusion criteria are described in Table 1.
After baseline measurements, including nasal provocation
and lung function tests, patients were diagnosed as having
atopic rhinitis, atopic asthma or AD according to preset
criteria, described extensively elsewhere [18, 19].
Follow-up visits were scheduled 4 and 12 months after
baseline measurements. All measurements were performed
outside the pollen season to avoid interference.
Randomization and blinding procedures
The study was designed as a double-blind, placebo-controlled
trial. The randomization procedure for all centres was per-
formed by the Julius Centre for Patient Oriented Research.
Each patient was assigned a research number. Research
number and bedding measures were sent to the manufacturer
of the encasings, HAL (Haarlem, the Netherlands). A carton
box, containing all encasings, was sent to the research centre,
with the research number written on the outside of the box.
Patients took the box home and opened it in the absence
of the research staff. Encasings for pillows, duvets and
mattresses were applied after baseline measurements.
Clinical measurements
Generic QOL was measured by means of the SF-36. We used
the translation of Aaronson of the MOS SF-36, originally
developed by Ware and co-workers [20–24]. SF-36 consists
of 36 questions divided over eight subscales, covering both
physical and mental health. Physical health subscales are
Physical functioning (PF), Role physical functioning (RP),
Bodily pain (BP) and General health (GH); mental health
subscales are Mental health (MH), Role emotional function-
ing (RE), Social functioning (SF) and Vitality (VT). Ques-
tions are stated in either yes/no form or multiple choice. Sum
score is calculated for each subscale and transformed to a
percentage of the total possible score. A high score indi-
cates good QOL, while a low score indicates lower QOL. The
reliability in two general population samples as reported by
Aaronson using Cronbach’s a varied from 0.76 to 0.92, while
the item discriminant validities varied from 0.09 to 0.64.
The RQLQ developed by Juniper and Guyatt [1] was used
to estimate the severity of complaints caused by AR. Patients
had to score 28 items comprising the following domains:
Nasal (NS) symptoms (four items), Practical problems (PP,
three items), Non-nasal (NN) symptoms (seven items), Sleep
(disorders) (SL, three items), (impairment of) Activities (Act,
three items), Eye symptoms (ES, four items) and Emotions
(EM, four items). They had to estimate their degree of
impairment on a 7-point scale (05not bothered, 65
extremely bothered).
SF-36 and RQLQ were administered to the patient before
tests were performed (e.g. the RQLQ was filled in prior to
nasal provocation with HDM). Trained personnel instructed
the patient according to the guidelines, defined by the design-
ers of the questionnaires. All patients filled in their question-
naires in a private room without the presence of other
persons.
As nasal complaints can be biased by use of medication, all
nasal medication was stopped. Oral antihistaminics were
stopped 17 days and nasal sprays 4–6 weeks before baseline
and follow-up visits to ensure a long enough wash-out period.
Patients were allowed to use acrivastine, 8mg 1–3 times a day,
but the use of rescue medication was discouraged.
Statistical analysis
Baseline variables for the impermeable cover group and non-
impermeable cover group were calculated with w2 test for
categorical variables and ANOVA for continuous data.
Analysis of the relationship between RQLQ and SF-36
was performed on the pooled data of the patients by means
of canonical correlations for continuous data [25–27]. A
condition of proper use of canonical correlation is that the
variables multivariately have a normal distribution. Second-
ly, linearity is assumed in canonical analysis. Finally, it is
important that the variables within and across each set are
not too highly intercorrelated. Squared multiple correlations
Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Age 8–50 years 1. Pets at home and positive skin test (indexX0.7) and/or RASTX2 for the pet
2. Not pregnant or lactating 2. Daily use of inhalation steroidsX1600 mcg/day (adults) or X800 mcg/day (children)
3. No encasings or willing to remove them for the period of the study 3. Daily use of oral steroids
4. Clinical history of AR and a positive nasal provocation test with HDM 4. Daily use of cyclosporine
5. RASTX2 [1] and/or i.c. skin test index [2] X0.7 for HDM 5. Regular use of antibiotics for upper or lower airway infection
6. X200 ng Der p 1 or Der f 1 in dust sample of mattress 6. Regular use of oral steroids for exacerbation of asthma
AR, allergic rhinitis; HDM, house dust mite; i.c., intracutaneous.
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as a measure to identify multicollinearity and singularity were
performed. Our data met the aforementioned criteria. BMDP
Statistical Software was used for all analyses.
We wanted to investigate the relationship between SF-
36 and RQLQ in terms of ‘explained variance’. Explained
variance is that part of the total variance of a variable that
can be estimated or predicted by another variable. For
example, if the explained variance of ‘NS complaints’ by PF is
0.40 then 40% of the variance of ‘NS complaints’ can be
predicted by PF. Otherwise stated, the overlap between ‘NS
complaints’ and PF is 40%.
Analysis was performed on the sumscores of the domains of
both questionnaires. Also, overlap between SF-36 and RQLQ
was calculated by means of redundancy analysis. The redun-
dancy is the average explained variance of the domains of one




At baseline, 224 patients were included in the study; 183
patients completed the study. Data eligible for analysis
were available for 160 patients. Loss to follow-up was not
significantly different between the placebo (17) and interven-
tion group (24) as were the reasons for leaving the study (data
not shown). At baseline, biographic data, severity of atopic
symptoms (assessed by visual analogue scale, SF-36, RQLQ)
and sensitization (assessed by RAST, skin tests, eosinophils)
were not significantly different in the placebo and interven-
tion group (data not shown). After 12 months, SF-36 and
RQLQ subscale scores were not significantly different in both
groups as well (data not shown).
Redundancy analysis
Tables 2a and b show the intercorrelation of SF-36 and
RQLQ. At baseline, VT and NN symptoms show consider-
able overlap ( 0.60). After 12 months, NN symptoms show
a more or less similar overlap with PF, RP, GH and VT. VT
also has a moderate overlap with EM after 12 months. The
results of the explained variance analysis (data not shown)
showed that the domain of NN complaints of the RQLQ had
a moderate overlap of 44% with SF-36. After 12 months, the
overlap was 57%. At baseline, the domain VT of the SF-36
had a moderate overlap with RQLQ of 40%; after 12 months
this percentage was 48%. The domain RP of SF-36 had
little overlap at baseline with RQLQ, but after 12 months the
explained variance was 41%. The overall redundancies for
RQLQ and SF-36 subscales were 16% and 22%, respectively,
at baseline. One year after the start of the study, these
percentages were 25 for RQLQ and 27 for SF-36 (Table 3).
Discussion
QOL questionnaires attempt to estimate the burden of
disease. In AR, both the generic SF-36 and the disease-
specific RQLQ have often been used [7–9, 28, 29, 1, 13, 30,
31]. It has been stated that generic instruments are more
tailored to evaluate the burden of disease across different
diseases, whereas specific instruments are more responsive for
changes in clinical trials [32]. Although both instruments aim
to evaluate QOL, it is not known whether these instruments
cover similar domains rather than different domains in QOL.
It is possible that some domains are covered better by one
instrument than by the other.
Recently, Juniper et al. reported a moderate correlation
between SF-36 and RQLQ [33]. The subjects tested were not
permitted to have symptoms other than those of rhinocon-
junctivitis. By focussing on subjects with rhinitis only, this
investigation gives a clear insight in the inter-relationship
between the two instruments by studying a homogeneous
patient population. It is, however, well known that rhinitis,
asthma and AD are closely associated. Atopy – the personal
or familial tendency to produce IgE antibodies to low-dose
antigens and to develop typical symptoms such as asthma,
rhinoconjunctivitis and AD – forms the basis of the close
Table 2. Intercorrelation matrix of RQLQ and SF-36
Act SL NN PP NS ES EM
(a) At baseline
PF 0.15 0.26 0.36  0.02  0.13  0.18 0.19
RP 0.23 0.37 0.49  0.18  0.28  0.25 0.34
GH 0.10 0.30 0.46  0.06  0.19  0.25 0.38
BP 0.23 0.33 0.38  0.02  0.11  0.17 0.35
SF 0.16 0.30 0.46  0.07  0.13  0.27 0.37
VT 0.20 0.33 0.60  0.13  0.25  0.33 0.46
MH 0.07 0.24 0.36  0.04  0.15  0.24 0.39
RE 0.02 0.12 0.30 0.02  0.13  0.13 0.27
(b) After 12 months
PF 0.31 0.37 0.58  0.27  0.26  0.29 0.36
RP 0.37 0.41 0.62  0.25  0.34  0.32 0.46
GH 0.29 0.30 0.52  0.28  0.25  0.37 0.42
BP 0.29 0.35 0.44  0.19  0.18  0.21 0.30
SF 0.26 0.38 0.41  0.28  0.27  0.28 0.40
VT 0.35 0.47 0.69  0.34  0.38  0.36 0.51
MH 0.25 0.24 0.43  0.22  0.19  0.27 0.42
RE 0.14 0.17 0.28  0.11  0.12  0.08 0.23
Act, (impairment of) Activities (Act, n5 3); BP, Bodily pain; EM, Emotions; ES,
Eye symptoms; GH, General health; MH, Mental health; NN, Non-nasal
symptoms; NS, Nasal symptoms; PF, Physical functioning; PP, Practical
problems; RE, Role emotional functioning; RP, Role physical functioning; SF,
Social functioning; SL, Sleep (disorders); VT, Vitality.
Table 3. Overall redundancy of RQLQ and SF-36 (pooled data)







Redundancy coefficients: the percentage of variance extracted from its own
set of variables multiplied by the canonical correlation squared for the pair.
Only the first pair was of significance.
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connection between these disorders [34]. Development of
allergic sensitization and diseases is partly under common
genetic control. Evidence for linkage between candidate loci
for allergic disease and total IgE concentrations is found in
the same regions for which reasonable evidence for linkage to
asthma has been reported [35].
The patient population of this study reflects the close
association between AR, asthma and AD as shown in a co-
morbidity percentage of 53% (data not shown). An explora-
tion of the inter-relation of SF-36 and RQLQ in this study
group as opposed to the rhinoconjunctivitis group of Juniper
was therefore a logical consequential step. The explained
variance analysis showed an overlap in the domains ‘NN
complaints’ of the RQLQ and VT of the SF-36; in the
intercorrelation matrix, ‘NN complaints’ also showed an
overlap with VT at baseline and after 12 months. It is not
surprising that these items of the RQLQ (i.e. being troubled
by fatigue, thirst, reduced productivity, tiredness, poor con-
centration, headache and being worn out as a consequence
of nose and eye symptoms) and the SF-36 VT domain
(comprising questions as ‘Did you feel full of pep?’, ‘Did you
have a lot of energy?’, ‘Did you feel worn out?’ and ‘Did you
feel tired?’) can be explained by the other instrument. The
same may hold true for the overlap of ‘NN complaints’ after
12 months with PF, RP and GH. Other domains of the SF-36
apparently have little overlap with the domains of the RQLQ
and vice versa. Overall redundancy coefficients were low, 0.16
and 0.21 for RQLQ and SF-36, respectively.
The overlap may be partly explained by our observation
that associated NN symptoms (i.e. asthma symptoms and SL
disorders) or disease (presence of asthma) influence generic
QOL [17]. That the redundancy is moderate can be part-
ly attributed to the fact that the measurements are fallible. It
had already been shown in the 1970s by Andrew and Withey
that a subjective QOL judgement contains about 60% valid
variance. The remaining variance comprises both the system-
atic and the random error variance.
In our analysis, we used the pooled data of the patients
under the assumption that a possible effect of the interven-
tion would affect SF-36 and RQLQ equally. However, it
is conceivable that the responsiveness of a disease-specific
instrument is better compared with a generic instrument. As
we could not demonstrate any effect of the covers on other
clinical end points [19] despite a significant reduction in
exposure to allergen, we find it improbable that such a dif-
ference in responsiveness would have appeared.
The results of questionnaires might be biased because of
errors of the measurement instrument such as distortion by
the format of questionnaire design or a patient’s disposition
to give socially desirable answers, to represent themselves as
better than they actually feel (faking good) or the opposite
(faking bad). A patient’s frame of references can change
considerably over time, as is known from oncology research,
[36, 37] and this response shift has to be taken into account in
all QOL research ranging over time.
However, neither the overlap between both instruments
changed substantially in 12 months, nor was a significant
change in scores on SF36 and RQLQ subscales observed.
These results are in line with our observation that the use of
impermeable covers for bedding does not have a beneficial
effect on AR [19], which excludes a differential effect of
treatment on the outcome of both instruments. Although
patients were monitored during 12 months, the findings do
not suggest a response shift.
The limited overlap between RQLQ and SF-36 may have
some consequences. The burden of rhinitis and the effect of
a pharmacological intervention focussed on rhinitis may be
best evaluated by a disease-specific questionnaire such as the
RQLQ. Recognizing the fact that AR forms a part of the
atopic syndrome and comes with other atopic disorders, AR
in the context of co-morbid associations may be best evalu-
ated by a generic instrument such as the SF-36. Therefore, the
use of both types of instruments simultaneously may be
advocated in the evaluation of the patient with AR.
In conclusion, in patients with HDM allergy characterized
by co-morbid associations SF-36 and RQLQ cover different
aspects in QOL and should be used simultaneously in per-
forming QOL studies.
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